| Contact, Use Central |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705) |
|
|
| Active, not recruiting | 3 | 136 | US | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo | CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI) | Graft Versus Host Disease (GVHD) | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 126 | Europe, Japan, US, RoW | human immunoglobulin G, IgPro20, Hizentra, Placebo | CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406 | Dermatomyositis | 06/24 | 11/27 | | |
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema |
|
|
| Recruiting | 3 | 20 | Europe, Canada, US, RoW | CSL312, Garadacimab | CSL Behring | Hereditary Angioedema (HAE) | 11/26 | 11/26 | | |
| Terminated | 3 | 194 | Europe, Canada, US, RoW | Clazakizumab, Physiologic saline solution | CSL Behring, ICON Clinical Research | Antibody-mediated Rejection | 04/24 | 04/24 | | |
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) |
|
|
| Recruiting | 3 | 35 | Canada, US, RoW | CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec | CSL Behring | Hemophilia B | 10/28 | 10/28 | | |
MODULAATE, NCT03805789: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant |
|
|
| Recruiting | 2/3 | 310 | Europe, Japan, US, RoW | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor, Placebo | CSL Behring | Acute-graft-versus-host Disease | 09/25 | 03/27 | | |
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis |
|
|
| Enrolling by invitation | 2/3 | 2310 | Europe, Canada, US, RoW | CSL300, Clazakizumab, Placebo | CSL Behring | Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease | 12/28 | 12/28 | | |
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® |
|
|
| Active, not recruiting | 2 | 81 | Europe, RoW | Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL | Astellas Pharma Europe Ltd. | Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation | 10/15 | 05/26 | | |
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
|
|
| Recruiting | 2 | 38 | US | TARA-002 | Protara Therapeutics | Lymphatic Malformation | 12/25 | 05/26 | | |
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 127 | US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 05/30 | 08/30 | | |
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects |
|
|
| Terminated | 1 | 52 | Europe | CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo | CSL Behring | Immune Complex-mediated Autoimmune Diseases | 03/23 | 03/23 | | |
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge |
|
|
| Completed | 1 | 40 | Europe | CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo | CSL Behring | Healthy Volunteers | 07/23 | 07/23 | | |
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers |
|
|
| Completed | 1 | 78 | Europe | Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo | CSL Behring | Asthma | 11/23 | 11/23 | | |
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1 | 12 | US | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 06/24 | 08/24 | | |
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) |
|
|
| Recruiting | 1 | 18 | Europe, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 06/24 | 07/24 | | |
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects |
|
|
| Recruiting | 1 | 60 | RoW | CSL040, Placebo | CSL Behring | Complement Deficiencies | 03/25 | 03/25 | | |
| Completed | N/A | 80 | Europe, US | | Protara Therapeutics | Intestinal Failure-associated Liver Disease | 06/23 | 06/23 | | |
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B |
|
|
| Recruiting | N/A | 500 | US | HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX) | CSL Behring | Hemophilia B | 08/43 | 08/43 | | |
| Essink, Brandon |
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) |
|
|
| Recruiting | 4 | 8600 | US | Naltrexone-Bupropion (NB) Combination, Placebo | Currax Pharmaceuticals | Obesity | 01/29 | 07/29 | | |
| Completed | 3 | 4223 | Europe, US | ABNCoV2, Comirnaty | Bavarian Nordic | COVID-19 Disease | 03/23 | 10/23 | | |
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older |
|
|
| Active, not recruiting | 3 | 7741 | Europe, Canada, US, RoW | Investigational aQIVc, licensed QIV1, licensed QIV2 | Seqirus | Influenza, Human | 03/24 | 01/25 | | |
NCT06374394: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above |
|
|
| Recruiting | 3 | 850 | Europe, US | RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 12/24 | 05/25 | | |
NCT06151288: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults |
|
|
| Active, not recruiting | 1/2 | 1015 | US | 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine, PCV20, Prevnar 20™ | Vaxcyte, Inc. | Pneumococcal Vaccines | 09/24 | 09/24 | | |
NCT05089630: A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults |
|
|
| Active, not recruiting | 1/2 | 329 | US | Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline) | GlaxoSmithKline | Cytomegalovirus Infections | 06/29 | 06/29 | | |
NCT04909021: Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months |
|
|
| Recruiting | 1c | 63 | US | Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose) | Meissa Vaccines, Inc. | Respiratory Syncytial Virus (RSV) | 10/23 | 10/23 | | |
NCT05664334: Safety and Immunogenicity of IVX-A12 in Healthy Older Adults |
|
|
| Completed | 1 | 140 | US | IVX-121, IVX-241, Placebo, MF59® | Icosavax, Inc. | Healthy | 01/24 | 01/24 | | |
NCT05477186: Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old |
|
|
| Completed | 1 | 180 | US, RoW | CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (75 μg), CV0501 (100 μg), CV0501 (150 μg), CV0501 (200 μg) | GlaxoSmithKline | COVID-19, SARS-CoV-2 | 08/23 | 08/23 | | |
NCT03569514: Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax |
|
|
| Not yet recruiting | N/A | 10 | NA | AIGIV, ANTHRASIL® | Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services | Anthrax | 07/26 | 07/26 | | |
NCT03569553: A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients |
|
|
| Not yet recruiting | N/A | 100 | NA | AIGIV, ANTHRASIL® | Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services | Inhalational Anthrax | 07/26 | 07/26 | | |
| Boomgaarden, Irene |
| No trials found |
